Toggle navigation
Home
Search
Services
Blog
Contact
About
Carbamazepine Formulation for IV Epilepsy Therapy
Violante, Michael R.
Sts Biopolymers, Inc., Henrietta, NY, United States
Search 16 grants from Michael Violante
Search grants from Sts Biopolymers, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Your institution
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Roles for FoxO proteins in human liver development
In vivo Core
Radiation sensitivity/Apoptosis Induction in Cancer Cells - P53 Restoration
Baculovirus Induced Nuclear Membrane Assembly
Studies of Left Ventricular Dysfunction
Recently added grants:
Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD
Mechanistic-based biomarkers of abusive alcohol consumption
Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
The neuropathology of mild traumatic brain injury in Alzheimer disease
Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44NS032243-03
Application #
2270269
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (18))
Program Officer
Kitt, Cheryl A
Project Start
1995-01-10
Project End
1996-12-31
Budget Start
1996-01-01
Budget End
1996-12-31
Support Year
3
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Sts Biopolymers, Inc.
Department
Type
DUNS #
City
Henrietta
State
NY
Country
United States
Zip Code
14467
Related projects
NIH 1996
R44 NS
Carbamazepine Formulation for IV Epilepsy Therapy
Violante, Michael R. / Sts Biopolymers, Inc.
NIH 1995
R44 NS
Carbamazepine Formulation for IV Epilepsy Therapy
Violante, Michael R. / Sts Biopolymers, Inc.
Comments
Be the first to comment on Michael Violante's grant